Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic cytolytic T lymphocytes (CTL). Two of these tumor rejection antigens, P815A and P815B, are encoded by gene P1A, the sequence of which was reported previously. Tumor cell variants having lost one or both of these antigens were isolated by in vitro selection with CTL and also by collecting tumor cells that progressed in vivo after escaping a nearly complete immune rejection process. The structure of gene P1A in these antigen-loss variants was examined. Several A-B- variants presented a complete or partial deletion of the gene. One variant that had lost only antigen A displayed a point mutation in the first exon. Peptides were synthesized that co...
Tumor evasion of T-cell immunity remains a significant obstacle to adoptive T-cell therapy. It is un...
Central tolerance toward tissue-restricted Ags is considered to rely on ectopic expression in the th...
P815 is a murine mastocytoma of DBA/2 origin which, although immunogenic, rapidly develops as a tumo...
Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic c...
Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic c...
We showed previously that mouse mastocytoma P815 expresses several distinct antigens that are recogn...
Mouse mastocytoma P815 expresses tumor antigens P815A and P815B encoded by a single gene called P1A ...
Murine mastocytoma P815 induces CTL responses against at least four distinct Ags (AB, C, D, and E), ...
Immunogenic tumor cell variant P35 was obtained by mutagen treatment of mouse mastocytoma P815. It e...
A number of human tumor antigens have been characterized recently using cytolytic T lymphocytes (CTL...
In murine mastocytoma P815, gene P1A directs the expression of antigens P815A and B which are the ta...
On the basis of the results reviewed here, there are two major mechanisms whereby tumour rejection a...
The cytolytic T lymphocyte (CTL) response of syngeneic mice to antigenic variants obtained by mutage...
Most chemically induced tumors of mice express unique antigens that can be recognized by cytotoxic T...
We reported previously that the mouse tumor P815 expresses four distinct antigens (A, B, C, D) recog...
Tumor evasion of T-cell immunity remains a significant obstacle to adoptive T-cell therapy. It is un...
Central tolerance toward tissue-restricted Ags is considered to rely on ectopic expression in the th...
P815 is a murine mastocytoma of DBA/2 origin which, although immunogenic, rapidly develops as a tumo...
Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic c...
Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic c...
We showed previously that mouse mastocytoma P815 expresses several distinct antigens that are recogn...
Mouse mastocytoma P815 expresses tumor antigens P815A and P815B encoded by a single gene called P1A ...
Murine mastocytoma P815 induces CTL responses against at least four distinct Ags (AB, C, D, and E), ...
Immunogenic tumor cell variant P35 was obtained by mutagen treatment of mouse mastocytoma P815. It e...
A number of human tumor antigens have been characterized recently using cytolytic T lymphocytes (CTL...
In murine mastocytoma P815, gene P1A directs the expression of antigens P815A and B which are the ta...
On the basis of the results reviewed here, there are two major mechanisms whereby tumour rejection a...
The cytolytic T lymphocyte (CTL) response of syngeneic mice to antigenic variants obtained by mutage...
Most chemically induced tumors of mice express unique antigens that can be recognized by cytotoxic T...
We reported previously that the mouse tumor P815 expresses four distinct antigens (A, B, C, D) recog...
Tumor evasion of T-cell immunity remains a significant obstacle to adoptive T-cell therapy. It is un...
Central tolerance toward tissue-restricted Ags is considered to rely on ectopic expression in the th...
P815 is a murine mastocytoma of DBA/2 origin which, although immunogenic, rapidly develops as a tumo...